EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The application of rituximab during the conditioning regimen prevents Epstein - Barr virus infection following rATG-based haploidentical hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis

Jinxia Hao, Tongxin Zhang, Juan Ren, Xiaoning Wang

Frontiers in Immunology · 19.06.2026 · 17

DOI: 10.3389/fimmu.2026.1795239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 19.06.2026. Verfasst von Jinxia Hao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Xi'an Jiaotong University Hospital, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Rituximab, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Epstein-Barr Virus Infections. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the era of letermovir for cytomegalovirus (CMV) prophylaxis, several centers reported that the incidence of Epstein-Barr virus (EBV) infection were significantly increased.

Objective

To investigate the efficacy and safety of rituximab administration during conditioning regimen following haploidentical hematopoietic stem cell transplantation(haplo-HSCT)in the prevention of post-transplant EBV infection.

Methods

We conducted a retrospective analysis of 100 patients with acute leukemia or myelodysplastic syndrome who underwent haplo-HSCT. Patients in observation group(R group) received rituximab (375 mg/m²) on day -3 before transplantation due to the presence of donor-specific antibody (MFI ≥ 2000) (n = 25) and patients in control group (C group) did not receive rituximab (n = 75) and donor-specific antibody was low (MFI < 2000). The primary objectives were the incidence of EBV-DNA viremia and PTLD within one-year post-transplantation. Secondary objectives included the incidence of CMV infection, cumulative incidence of acute graft-versus-host disease (aGVHD) and chronic GVHD, 100-day non-relapse mortality (NRM), progression-free survival (PFS), and overall survival (OS).

Results

No significant differences were observed in baseline characteristics between the two groups except for primary disease. When compared with the C group, patients in R group exhibited a lower cumulative incidence of EBV viremia within one-year post - transplantation (4.00% vs. 22.67%, P = 0.049) and a lower incidence of aGVHD (28% vs. 50.67%, P = 0.048). There was a trend toward reduction of PTLD in the R group compared with C group (0% vs. 10.67%, P = 0.089).There were no significant differences of the incidence of CMV viremia (24% vs. 13.33%, P = 0.208), cGVHD (16% vs. 12%, P = 0.607), and 100 - day NRM (4.0% vs. 10.67%, P = 0.313) between two groups. The 2-year OS rates in the R group and C group were 83.8% ± 0.086% and 81.9% ± 0.050% respectively (P = 0.360). The 2-year PFS rates in the R group and C group were 83.8% ± 0.086% and 72.6% ± 0.068% respectively (P = 0.360).

Conclusion

The combined use of rituximab during the conditioning regimen may be regarded as an effective strategy for preventing EBV reactivation after rATG - based haplo - HSCT in the era of letermovir for CMV prophylaxis.Prospective randomized controlled trials are still required to further validate the reliability of the results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabHematopoietic Stem Cell TransplantationTransplantation ConditioningEpstein-Barr Virus InfectionsCytomegalovirus InfectionsQuinazolinesAcetatesHumansFemaleMaleAdultRetrospective StudiesMiddle AgedGraft vs Host DiseaseAdolescentHerpesvirus 4, HumanYoung AdultAntiviral AgentsTransplantation, HaploidenticalCytomegalovirusTreatment OutcomeAnimalsMyelodysplastic Syndromes

Stichwörter der Autor:innen

EBV viremiaacute graft-versus-host diseasehaploidentical hematopoietic stem cell transplantationpost-transplant lymphoproliferative disordersrituximab

Substanzen

RituximabletermovirQuinazolinesAcetatesAntiviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Xi'an Jiaotong University Hospital, Xi'an, Shaanxi, China.
  • Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Zitieren

APA

Hao, J., Zhang, T., Ren, J., & Wang, X. (2026). The application of rituximab during the conditioning regimen prevents Epstein - Barr virus infection following rATG-based haploidentical hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1795239

Vancouver

Hao J, Zhang T, Ren J, Wang X. The application of rituximab during the conditioning regimen prevents Epstein - Barr virus infection following rATG-based haploidentical hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1795239

BibTeX
@article{Hao2026,
  author = {Hao, Jinxia and Zhang, Tongxin and Ren, Juan and Wang, Xiaoning},
  title = {The application of rituximab during the conditioning regimen prevents Epstein - Barr virus infection following rATG-based haploidentical hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1795239}
}
Kostenlos starten →